Tirzepatide vs Semaglutide: Key Clinical Differences

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, tirzepatide is not a compounded semaglutide—they are two distinct dual or single-action GLP-1 receptor agonists with different chemical structures and clinical profiles. Tirzepatide is a GIP/GLP-1 receptor co-agonist approved by the FDA for type 2 diabetes and weight management, while semaglutide is a GLP-1 only agonist used for similar indications. Understanding these differences is critical for informed treatment selection.

Many patients and even some providers conflate these medications because both belong to the GLP-1 class. However, their mechanism of action, efficacy data, side effect profiles, and suitability for different patient populations vary significantly. Precision-focused care requires recognizing that genetic and biomarker factors may influence how each medication performs in individual patients.

Mechanism of Action: Single vs. Dual-Receptor Activity

Semaglutide activates only the GLP-1 receptor, triggering glucose-dependent insulin secretion, slowed gastric emptying, and appetite reduction. This single-pathway mechanism has been well-studied in clinical populations for over a decade. Tirzepatide, approved more recently, activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously.

The dual-receptor mechanism of tirzepatide may produce greater weight loss and glucose control in some patients compared to semaglutide alone, according to head-to-head trials. However, this dual activation also carries distinct tolerability considerations. Individual genetic variation in GLP1R and GIPR expression may influence how each pathway responds in a given patient.

Clinical Efficacy, Safety Profile, and Individual Variation

Both medications demonstrate significant glycemic control and weight reduction in clinical trials. Tirzepatide typically shows 20-22% body weight reduction at maximum doses, while semaglutide averages 14-17% depending on dose and population. Side effect severity and frequency, particularly gastrointestinal tolerability, varies between individuals and may relate to genetic predispositions in peptide receptor pathways.

Factor	Semaglutide (GLP-1 Only)	Tirzepatide (GIP/GLP-1 Co-agonist)
FDA Approvals	Type 2 diabetes, weight loss, cardiovascular benefits	Type 2 diabetes, weight loss
Average Weight Loss	14-17% body weight	20-22% body weight
Primary Mechanism	GLP-1 receptor agonism only	Dual GIP and GLP-1 receptor agonism
Typical GI Side Effects	Nausea, vomiting (dose-dependent)	Nausea, vomiting (often greater initial severity)
Time to Market	FDA-approved 2017 (semaglutide)	FDA-approved 2022 (tirzepatide)

Compounding Status: Why Pharmacy Source Matters

Both semaglutide and tirzepatide are available in branded formulations (Ozempic, Wegovy, Mounjaro, Zepbound) and as compounded preparations from licensed 503A pharmacies. Compounded versions offer cost flexibility and dosing customization but lack the same manufacturing standardization as branded products. PlexusDx sources all compounded medications exclusively from licensed 503A compounding pharmacies.

Patients considering compounded tirzepatide or semaglutide should confirm their source meets 503A standards and understand that compounded formulations differ from FDA-approved branded products. A qualified healthcare provider should evaluate whether compounded or branded options align with individual clinical needs, insurance coverage, and access constraints.

Who Benefits From Each Option: Genetic and Clinical Considerations

Patients with severe insulin resistance or marked hyperglycemia may respond more robustly to tirzepatide's dual-receptor mechanism. Conversely, those with milder metabolic dysfunction, cardiovascular disease history, or concern about gastrointestinal side effects may benefit from semaglutide's single-pathway profile. Genetic variants in GLP1R (rs6923761) and GIPR (rs1800437) may influence receptor sensitivity and medication response.

Your healthcare provider should assess metabolic biomarkers, comorbidities, prior medication tolerability, and treatment goals before selecting tirzepatide or semaglutide. Genetic insights into peptide receptor predispositions can complement clinical evaluation but should never replace comprehensive medical assessment. Individual variation in efficacy and tolerability is expected and can be monitored through follow-up metabolic labs and symptom assessment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R and GIPR pathways—the biological targets of semaglutide and tirzepatide. These variants may help provide context regarding predispositions in peptide receptor function and metabolism-related genes like FTO and MC4R. This information, interpreted with your qualified healthcare provider, can support more informed conversations about medication selection.

The genetic test does not predict which medication will work best or guarantee specific outcomes; rather, it reveals predispositions in peptide genetic pathways that may influence metabolic response patterns. Some patients carry variants associated with greater GLP-1 receptor sensitivity, while others show predispositions toward different metabolic phenotypes. Understanding these patterns alongside clinical data helps your provider tailor a more personalized approach.

When considering compounded tirzepatide or semaglutide, combining genetic insights with biomarker monitoring—glucose, lipids, weight, gastrointestinal tolerance—creates a more comprehensive precision-medicine framework. PlexusDx helps patients and providers use this multi-dimensional information to optimize selection and adjustment of GLP-1 or GIP/GLP-1 therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.